

# Mauro Schechter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8312294/publications.pdf>

Version: 2024-02-01

90  
papers

18,632  
citations

57719

44  
h-index

43868

91  
g-index

94  
all docs

94  
docs citations

94  
times ranked

14060  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. <i>New England Journal of Medicine</i> , 2010, 363, 2587-2599.	13.9	4,268
2	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. <i>New England Journal of Medicine</i> , 2015, 373, 795-807.	13.9	2,232
3	Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 820-829.	4.6	1,039
4	Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. <i>Lancet</i> , The, 2006, 367, 817-824.	6.3	1,030
5	Antiretroviral Therapy in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 381.	3.8	951
6	Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. <i>Science Translational Medicine</i> , 2012, 4, 151ra125.	5.8	807
7	Treatment for Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 827.	3.8	755
8	Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 339-354.	13.9	699
9	Antiretroviral Treatment for Adult HIV Infection in 2002. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 222.	3.8	632
10	Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. <i>New England Journal of Medicine</i> , 2008, 359, 355-365.	13.9	498
11	Treatment for Adult HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 251.	3.8	482
12	Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. <i>Lancet</i> , The, 2010, 376, 367-387.	6.3	431
13	Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. <i>Aids</i> , 2013, 27, 973-979.	1.0	315
14	Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. <i>Bulletin of the World Health Organization</i> , 2008, 86, 559-567.	1.5	275
15	HIV-1 DNA predicts disease progression and post-treatment virological control. <i>ELife</i> , 2014, 3, e03821.	2.8	270
16	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society's Lancet Commission. <i>Lancet</i> , The, 2018, 392, 312-358.	6.3	230
17	Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1. <i>PLoS Medicine</i> , 2004, 1, e19.	3.9	220
18	Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. <i>Clinical Infectious Diseases</i> , 2010, 50, 605-612.	2.9	196

#	ARTICLE	IF	CITATIONS
19	Short-Course Antiretroviral Therapy in Primary HIV Infection. <i>New England Journal of Medicine</i> , 2013, 368, 207-217.	13.9	194
20	Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. <i>Aids</i> , 2009, 23, 2289-2300.	1.0	164
21	Reduced Risk of Tuberculosis among Brazilian Patients with Advanced Human Immunodeficiency Virus Infection Treated with Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2002, 34, 543-546.	2.9	161
22	Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2015, 61, 572-580.	2.9	132
23	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). <i>PLoS ONE</i> , 2011, 6, e21225.	1.1	131
24	Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 922-926.	2.5	128
25	Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. <i>International Journal of Epidemiology</i> , 2007, 36, 969-976.	0.9	120
26	Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 587-596.	4.6	119
27	Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 70-77.	1.5	104
28	Community-Based Interventions to Improve and Sustain Antiretroviral Therapy Adherence, Retention in HIV Care and Clinical Outcomes in Low- and Middle-Income Countries for Achieving the UNAIDS 90-90-90 Targets. <i>Current HIV/AIDS Reports</i> , 2016, 13, 241-255.	1.1	94
29	Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e22003.	1.1	93
30	Dual and Recombinant Infections: An Integral Part of the HIV-1 Epidemic in Brazil. <i>Emerging Infectious Diseases</i> , 1999, 5, 65-74.	2.0	90
31	Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis. <i>Virus Genes</i> , 1996, 13, 69-81.	0.7	89
32	Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. <i>Tropical Medicine and International Health</i> , 2009, 14, 1220-1225.	1.0	78
33	Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy. <i>PLoS ONE</i> , 2013, 8, e78287.	1.1	74
34	Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. <i>International Journal of Epidemiology</i> , 2005, 34, 979-986.	0.9	72
35	Mortality after failure of antiretroviral therapy in sub-Saharan Africa. <i>Tropical Medicine and International Health</i> , 2010, 15, 251-258.	1.0	71
36	Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. <i>Lancet HIV</i> , the, 2016, 3, e521-e528.	2.1	66

#	ARTICLE	IF	CITATIONS
37	Validation of a Hierarchical Deterministic Record-Linkage Algorithm Using Data From 2 Different Cohorts of Human Immunodeficiency Virus-Infected Persons and Mortality Databases in Brazil. <i>American Journal of Epidemiology</i> , 2008, 168, 1326-1332.	1.6	65
38	Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx262.	0.4	65
39	Overcoming resistance to existing therapies in HIV-infected patients: The role of new antiretroviral drugs. <i>Journal of Medical Virology</i> , 2008, 80, 565-576.	2.5	56
40	Increase in Non-AIDS Related Conditions as Causes of Death among HIV-Infected Individuals in the HAART Era in Brazil. <i>PLoS ONE</i> , 2008, 3, e1531.	1.1	51
41	Monotherapy with Lopinavir/Ritonavir as Maintenance After HIV-1 Viral Suppression: Results of a 96-Week Randomized, Controlled, Open-Label, Pilot Trial (KalMo Study). <i>HIV Clinical Trials</i> , 2009, 10, 368-374.	2.0	50
42	Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. <i>Clinical Infectious Diseases</i> , 2018, 67, 411-419.	2.9	50
43	Horizontal and Vertical Transmission of Human Immunodeficiency Virus Type 1 Dual Infections Caused by Viruses of Subtypes B and C. <i>Journal of Infectious Diseases</i> , 1998, 177, 227-231.	1.9	48
44	Rates and Reasons for Early Change of First HAART in HIV-1-Infected Patients in 7 Sites throughout the Caribbean and Latin America. <i>PLoS ONE</i> , 2010, 5, e10490.	1.1	47
45	Modeling the Slow CD4+ T Cell Decline in HIV-Infected Individuals. <i>PLoS Computational Biology</i> , 2015, 11, e1004665.	1.5	46
46	Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. <i>Aids</i> , 2001, 15, 2129-2135.	1.0	43
47	The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study. <i>AIDS and Behavior</i> , 2016, 20, 1527-1534.	1.4	41
48	Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities. <i>Clinical Infectious Diseases</i> , 2018, 66, 1487-1491.	2.9	41
49	Triple nucleoside treatment with abacavir plus the lamivudine/ zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). <i>Current Medical Research and Opinion</i> , 2004, 20, 1103-1114.	0.9	40
50	Discordant immunological and virological responses to antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 506-510.	1.3	40
51	Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. <i>Clinical Infectious Diseases</i> , 2016, 62, 1172-1177.	2.9	40
52	HIV Disease Progression and V3 Serotypes in Brazil: Is B Different from B-Br?. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 953-958.	0.5	38
53	Rating evidence in treatment guidelines. <i>Aids</i> , 2013, 27, 1839-1846.	1.0	38
54	Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1945-1955.	3.1	38

#	ARTICLE	IF	CITATIONS
55	Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection. <i>Journal of the International AIDS Society</i> , 2014, 17, 19480.	1.2	37
56	Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil. <i>International Journal of STD and AIDS</i> , 2006, 17, 473-478.	0.5	36
57	Continuous Increase of Cardiovascular Diseases, Diabetes, and Non-HIV Related Cancers as Causes of Death in HIV-Infected Individuals in Brazil: An Analysis of Nationwide Data. <i>PLoS ONE</i> , 2014, 9, e94636.	1.1	35
58	Genetic Variation and Susceptibilities to Protease Inhibitors among Subtype B and F Isolates in Brazil. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 253-258.	1.4	35
59	Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression. <i>Aids</i> , 2014, 28, 869-874.	1.0	30
60	Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. <i>Lancet HIV</i> , 2018, 5, e172-e180.	2.1	28
61	Antiretroviral therapy in resource-poor settings: scaling up inequalities?. <i>International Journal of Epidemiology</i> , 2005, 34, 509-512.	0.9	27
62	Prevalence and risk factors associated with syphilis in a cohort of HIV positive individuals in Brazil. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 252-258.	0.6	25
63	Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. <i>Current Medical Research and Opinion</i> , 2004, 20, 1115-1123.	0.9	21
64	Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy. <i>Journal of Infection</i> , 2006, 52, 290-293.	1.7	20
65	Sequence and Phylogenetic Analysis of Glycoprotein 120 of an HIV Type 1 Variant (GWGR) Prevalent in Brazil. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 1143-1145.	0.5	17
66	Limited Penetration of Lopinavir and Ritonavir in the Genital Tract of Men Infected with HIV-1 in Brazil. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 175-179.	1.0	16
67	Estimating the Extent of Underreporting of Mortality Among HIV-Infected Individuals in Rio de Janeiro, Brazil. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 25-28.	0.5	16
68	The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels. <i>Aids</i> , 2015, 29, 1355-1361.	1.0	16
69	Monitoring Antiretroviral Therapy in Resource-Limited Settings: Balancing Clinical Care, Technology, and Human Resources. <i>Current HIV/AIDS Reports</i> , 2010, 7, 168-174.	1.1	15
70	Evaluation of Three Sampling Methods to Monitor Outcomes of Antiretroviral Treatment Programmes in Low- and Middle-Income Countries. <i>PLoS ONE</i> , 2010, 5, e13899.	1.1	13
71	Protease inhibitors as initial therapy for individuals with an intermediate risk of HIV disease progression: is more necessarily better?. <i>Aids</i> , 1999, 13, 97-102.	1.0	11
72	Streamlining HIV Testing for HIV Preexposure Prophylaxis. <i>Journal of Clinical Microbiology</i> , 2015, 53, 179-183.	1.8	10

#	ARTICLE	IF	CITATIONS
73	Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 788-793.	0.5	8
74	Risk-based assessment does not distinguish between recent and chronic HIV-1 infection in Rio de Janeiro, Brazil. <i>Brazilian Journal of Infectious Diseases</i> , 2009, 13, 272-5.	0.3	7
75	Monotherapy with lopinavir/ritonavir. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 735-741.	1.9	6
76	The Use of Supplementary Techniques to Increase Recall of Sex Partners in a Network-Based Research Study in Rio de Janeiro, Brazil. <i>Sexually Transmitted Diseases</i> , 2008, 35, 674-678.	0.8	6
77	Duration of Anti-Tuberculosis Therapy and Timing of Antiretroviral Therapy Initiation: Association with Mortality in HIV-Related Tuberculosis. <i>PLoS ONE</i> , 2013, 8, e74057.	1.1	5
78	Prioritization of antiretroviral therapy in patients with high CD4 counts, and retention in care: lessons from the START and Temprano trials. <i>Journal of the International AIDS Society</i> , 2018, 21, e25077.	1.2	5
79	p24 antigenaemia in HIV-1 infected Brazilians correlates with other markers of disease progression. <i>Journal of Infection</i> , 1994, 29, 129-131.	1.7	4
80	Late Diagnosis of HIV Infection in Brazil Despite over 15 Years of Free and Universal Access to Treatment. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1541-1542.	0.5	4
81	Reactivity to Purified Protein Derivative and the Risk of Tuberculosis in HIV-infected Brazilian Patients. <i>Chest</i> , 1993, 104, 646.	0.4	3
82	V3 peptide binding pattern and HIV-1 transmission route in Rio de Janeiro. <i>Memorias Do Instituto Oswaldo Cruz</i> , 1995, 90, 683-685.	0.8	3
83	A Brazilian perspective. <i>Lancet, The</i> , 1997, 349, S29-S30.	6.3	3
84	The DART Trial: 'The Doctor's Dilemma' revisited. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 964-967.	1.3	3
85	Mortality of HIV-infected patients in low-income countries – Authors'™ response. <i>Lancet, The</i> , 2006, 368, 2207-2208.	6.3	2
86	Reply to Kojima and Klausner. <i>Clinical Infectious Diseases</i> , 2018, 67, 1469-1470.	2.9	1
87	Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors. <i>PLoS ONE</i> , 2019, 14, e0222183.	1.1	1
88	Is France Once Again Looking for a Scapegoat?. <i>Pathogens and Immunity</i> , 2021, 6, 149-152.	1.4	1
89	Pulmonary Tuberculosis in Sputum-Negative Brazilian AIDS Patients. <i>Chest</i> , 1992, 101, 1184.	0.4	0
90	International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status. <i>Sexually Transmitted Diseases</i> , 2017, 44, 306-309.	0.8	0